



May 23, 2018

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

COMPANY CODE : 506285
SCRIP CODE : BAYERCROP

Dear Sir / Madam,

Sub.: News Release - Audited Financial Results for the financial year ended on March 31, 2018

We send herewith a copy of the News Release that is being issued by the Company today, in connection with the captioned subject.

You are requested to kindly take note of the same.

Thanking you.

Yours faithfully,
For Bayer CropScience Limited


Rajiv Wani
Head - Law, Patents & Compliance
& Company Secretary

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com



Bayer Group in India
Communications
Bayer House, Central Avenue
Hiranandani Estate
Thane (West) - 400607
Maharashtra, India
Boardline: +9122-25311234
Website: www.bayer.in

News Release

Financial Results

Bayer CropScience Limited reports Q4 and annual results for FY 2017-18

- FY 2017-18: Revenue from Operations of Rs. 27,490 million and Profit for the year of Rs. 3,001 million
 - Q4 2017-18: Revenue from Operations of Rs. 3,002 million and Loss for the quarter of Rs.129 million
-

Mumbai, May 23, 2018: Bayer CropScience Limited (BSE: 506285) announced its audited results for the financial year (FY) ending March 31, 2018. The Company registered Revenue from Operations of Rs. 27,490 million for FY 2017-18 as compared to Rs. 29,484 million in the previous year. Revenue from Operations of FY 2016-17 and FY 2017-18 upto June 30, 2017 included excise duty. The Company reported Profit for the year of Rs. 3,001 million.

Commenting on the financial results, Richard van der Merwe, Vice Chairman & Managing Director, Bayer CropScience Limited, said, "We are satisfied with the business performance for FY 2017-18, given the challenging business environment and the change-over to the new GST system."

On the future outlook for Bayer CropScience Limited, Mr. van der Merwe said, "We remain confident that FY 2018-19 will be a year of positive growth for the company, given the favorable monsoon predictions. In the months ahead, we plan to launch 8 to 10 new products across our Crop Protection, Seeds and Environmental Science portfolio, subject to receiving regulatory approvals. Farmers will be able to benefit from these new products in both Kharif 2018 and 2019."

For the quarter ended March 31, 2018, the Company registered Revenue from Operations of Rs. 3,002 million as compared to Rs. 2,380 million in the corresponding quarter of FY 2016-17. Loss for the quarter ended March 31, 2018 stood at Rs.129 million, as compared to Rs. 361 million posted in the corresponding quarter of FY 2016-17.

The Board of Directors have recommended a dividend payment of Rs.18 per equity share of Rs.10 each for the financial year ended March 31, 2018, subject to the shareholders' approval.

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.

Media Contact

Saswati Panigrahi

Crop Science Communications, Bayer Group in India

Tel. +91-22-25311097

E-mail: saswati.panigrahi@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.